Multiple Sclerosis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of MS for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s MS forecast will answer the following questions:

• Of all people diagnosed with MS, how many in each country in the developed world are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 16 MS patient populations, including the following:

• Diagnosed MS prevalent cases
• Diagnosed RR-MS prevalent cases.
• Diagnosed PP-MS prevalent cases.
• Diagnosed SP-MS prevalent cases.
• Diagnosed CIS prevalent cases.
• Diagnosed MS incident cases
• Diagnosed RR-MS incident cases.
• Diagnosed PP-MS incident cases.
• Diagnosed CIS incident cases.
• Diagnosed drug-treated MS prevalent cases
• Diagnosed drug-treated RR-MS prevalent cases.
• Diagnosed drug-treated PP-MS prevalent cases.
• Diagnosed drug-treated SP-MS prevalent cases.
• Diagnosed drug-treated CIS prevalent cases.
• … and many more (details available on request).

Note: Coverage may vary by country.